<DOC>
	<DOC>NCT01877785</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled, single-ascending dose study will assess the safety, tolerability and pharmacokinetics of ascending doses of MHAA4549A in healthy volunteers. Volunteers will be randomized to receive a single dose of MHAA4549A or matching placebo.</brief_summary>
	<brief_title>A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy volunteers Body mass index (BMI) between 18 and 32 kg/m2, inclusive Weight 40 to 100 kg In good health, determined by no clinically significant findings from medical history, 12lead ECG, and vital signs Clinical laboratory evaluations should be within the reference range for the test laboratory unless deemed not clinically significant by the investigator and Sponsor Volunteers agree to use acceptable contraceptive measures History or clinically significant manifestations of disorders History of anaphylaxis, hypersensitivity or drug allergies History or presence of an abnormal ECG History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit History of significant drug abuse within 1 year prior to screening Current tobacco smokers Positive drug screen at screening or at checkin Positive pregnancy test result at screening or Day 1 or breast feeding during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>